Namita Thapar’s Emcure Pharma Sees 5% Stock Surge After Jefferies’ ‘Buy’ Rating Initiation
Emcure Pharmaceuticals, backed by Namita Thapar, has achieved its first ‘buy’ rating since its market debut over a month ago. Jefferies has set a target price of ₹1,600 for the stock, suggesting a potential upside...